Competitive Grants Program
Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.
Sign up to receive all grant announcements, including Request for Proposal (RFP) postings.
Sign Up for Alerts DetailsTitle Grant Type Focus Area Country Application Due Date Optimizing RSV diagnosis by improving RSV detection in patients admitted to ED/hospitalized due to respiratory symptomsRelease Date:Quality Improvement Vaccines Austria, Belgium, Bulgaria, Czech Republic, Finland, Greece, Ireland, Israel, Luxembourg, Netherlands, Norway, Poland, Portugal, Romania, Slovakia (Slovak Republic), Sweden, Switzerland Investigating the Benefit of Early Treatment with Ritlecitinib in Alopecia Areata: A Real-World Evidence ApproachRelease Date:Research Inflammation & Immunology USA Guideline Concordant Care and Emerging Data for Patients with MIBC through la/mUCEducation Oncology USA Advancing Genomic Competence and Patient Centered Care in Metastatic Breast CancerRelease Date:Education Oncology Canada, China, France, Germany, India, Italy, Japan, Spain, United Kingdom AI-Enabled Models for Timely COVID-19 Treatment with Nirmatrelvir/Ritonavir: Eligibility & Drug–Drug Interaction ManagementRelease Date:Research Internal Medicine Australia, Canada, Germany, Greece, Japan, Korea, Taiwan Clinical Data Updates on Long Term Outcomes and Practical Therapy Management Strategies in First-line ALK-positRelease Date:Education Oncology United States Minor Outlying I OPTIMA-HEMA Project: Optimizing the Management and Application of Novel Immunotherapies in Hematologic MalignanciesRelease Date:Quality Improvement Oncology China Advancing Adult Immunization Strategies:A Focus on the Impact of Respiratory Syncytial Virus(RSV) and Cardiorespiratory OutcomeRelease Date:Education Vaccines USA Implementing Shared Decision Making in Hemophilia Patient CareRelease Date:Quality Improvement Rare Disease USA Transthyretin Cardiac Amyloidosis FellowshipRelease Date:Fellowship Internal Medicine Germany Title Grant Type Focus Area Country Application Due Date INNOVAtive Multi-disciplinary Clinical Management of INflammatory Diseases, 2023 IT INNOVA-MINDRelease Date:Quality Improvement Inflammation & Immunology Italy Quality Improvement in Pediatric Endocrinology FieldsRelease Date:Partner: The Japanese Society for Pediatric EndocrinologyQuality Improvement Rare Disease Japan Biomarker Testing / Lung CancerRelease Date:Education Oncology Japan Employment Support / Lung CancerRelease Date:Education Oncology Japan 2023 Oncology FellowshipRelease Date:Fellowship Oncology Canada Approaches to Implement Bispecific Antibodies into Clinical Practice, Increase Awareness and Improve Delivery of Quality of CareRelease Date:Partner: Myeloma CanadaQuality Improvement Oncology Canada Improving Health Equity via Clinical Trial Capability Development in ChinaRelease Date:Education Support for the Professions China Combination Therapy with Relugolix in the Treatment of Advanced Prostate CancerRelease Date:Partner: National Comprehensive Cancer Network; Myovant SciencesResearch Oncology USA Optimizing Women’s Health Conditions in CanadaRelease Date:Quality Improvement Internal Medicine Canada Women’s HealthRelease Date:Education Internal Medicine Canada Accelerating Advancements in Women’s HealthResearch Internal Medicine USA Implementing Rapid Turnaround Time for NGS Molecular Testing for Cancer Patients in Non-Academic and Community CentresRelease Date:Partner: Colorectal Cancer Canada and Thermo Fisher ScientificQuality Improvement Oncology Canada